Literatura académica sobre el tema "Adjuvant 5-Fluorouracil"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Adjuvant 5-Fluorouracil".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Adjuvant 5-Fluorouracil"
Nimeiri, Halla Sayed, Yang Feng, Paul J. Catalano, Neal J. Meropol, Bruce J. Giantonio, Elin R. Sigurdson, James A. Martenson et al. "Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e14711-e14711. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14711.
Texto completoAsaria, Riaz Hassan Yusuf, Chee Hing Kon, Catey Bunce, David G. Charteris, David Wong, Peng Tee Khaw y George William Aylward. "Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy". Ophthalmology 108, n.º 7 (julio de 2001): 1179–83. http://dx.doi.org/10.1016/s0161-6420(01)00589-9.
Texto completoAmonkar, Sunil J., Henry J. Cain, Tracey Hughes, J. Diane Hemming y David A. Browell. "Adjuvant 5-Fluorouracil-Induced Colitis Necessitating Completion Colectomy". Journal of Gastrointestinal Cancer 42, n.º 4 (6 de enero de 2011): 275–77. http://dx.doi.org/10.1007/s12029-010-9241-1.
Texto completoHill, GeorgeJ, L. Peter Fielding, Rosemary Hittinger, RogerH Grace y JohnS Fry. "Adjuvant treatment with 5-fluorouracil for colorectal cancer". Lancet 340, n.º 8831 (noviembre de 1992): 1349–50. http://dx.doi.org/10.1016/0140-6736(92)92530-s.
Texto completoKizilbash, Sani Haider, Kevin Ward, Ishmael A. Jaiyesimi y Joseph Lipscomb. "Survival outcomes in patients with early-stage, resectable pancreatic cancer: A comparison of gemcitabine and 5-fluorouracil based chemotherapy and chemoradiation regimens." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): e14608-e14608. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14608.
Texto completoKelder, Wendy, Geke A. P. Hospers y John T. M. Plukker. "Effects of 5-fluorouracil adjuvant treatment of colon cancer". Expert Review of Anticancer Therapy 6, n.º 5 (mayo de 2006): 785–94. http://dx.doi.org/10.1586/14737140.6.5.785.
Texto completoVaillant, Jean-Christophe, Bernard Nordlinger, Sylvie Deuffic, Jean-Pierre Arnaud, Edouard Pelissier, Jean-Pierre Favre, Daniel Jaeck et al. "Adjuvant Intraperitoneal 5-Fluorouracil in High-Risk Colon Cancer". Annals of Surgery 231, n.º 4 (abril de 2000): 449–56. http://dx.doi.org/10.1097/00000658-200004000-00001.
Texto completoMerendino, R. A., A. Ruello, S. Cascinu, B. Ferlazzo, A. Bene, D. Bonanno, P. Quattrocchi, N. Caristi y S. Gangemi. "Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients". International Journal of Biological Markers 17, n.º 1 (enero de 2002): 63–66. http://dx.doi.org/10.1177/172460080201700108.
Texto completoDencausse, Y., G. Hartung, J. Sturm, A. Kopp-Schneider, E. Hagmüller, C. Wojatschek, H. Lindemann, D. Fritze y W. Queisser. "Adjuvant Chemotherapy in Stage III Colon Cancer with 5-Fluorouracil and Levamisole versus 5-Fluorouracil and Leucovorin". Oncology Research and Treatment 25, n.º 5 (2002): 426–30. http://dx.doi.org/10.1159/000067436.
Texto completoBertuccelli, Maurizio, Francesco Cartei, Alfredo Falcone, Salvatrice Campoccia, Aldo Sainato, Francesco Ducci, Stefano Moda et al. "Postoperative Adjuvant Chemoradiotherapy for Rectal Cancer: Analysis of Acute and Chronic Toxicity". Tumori Journal 83, n.º 2 (marzo de 1997): 599–603. http://dx.doi.org/10.1177/030089169708300224.
Texto completoTesis sobre el tema "Adjuvant 5-Fluorouracil"
Edler, David. "Thymidylate synthase expression in colorectal cancer : its role as a prognostic factor and a predictive factor in adjuvant 5-fluorouracil-based chemotherapy /". Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4651-5/.
Texto completoBeare, Sandra Louise. "The capacity of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms to predict outcome after adjuvant cyclophosphamide, methotrexate and 5-fluorouracil in patients with early breast cancer". Thesis, University of Newcastle Upon Tyne, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.555994.
Texto completoCushing, Merta y Thao Truong. "Efficacy and toxicity of capecitabine/oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) in adjuvant and metastatic treatment of colorectal cancer in patients at the Southern Arizona Veteran Affairs Health Care System". The University of Arizona, 2017. http://hdl.handle.net/10150/624166.
Texto completoObjectives: To determine the efficacy and toxicity of fluorouracil/leucovorin/oxaliplatin (FOLFOX) versus capecitabine/oxaliplatin (XELOX) in the treatment of colorectal cancer (CRC) in the adjuvant (aCRC) and metastatic (mCRC) setting in Veterans at the Southern Arizona Veteran Affairs Health Care System (SAVAHCS). Methods: A retrospective chart review was conducted to collect efficacy and toxicity data. Subjects were included based on age, treatment setting and regimen in the preset 5-year period, and appropriate diagnosis via International Classification of Diseases-Revision 9 (ICD-9) codes. Efficacy was measured via 1-year disease-free survival (DFS) for aCRC, progression-free survival (PFS) for mCRC, and overall survival (OS) for both settings. Results: A total of 79 subjects were initially enrolled with 51 and 54 all-male subjects included in the efficacy and toxicity analysis, respectively. Mean range of age was 63-72 years old. Subjects were divided into four groups: FOLFOX aCRC (17) and mCRC (19), XELOX aCRC (10) and mCRC (8). No difference was found in 1-year DFS and OS between aCRC groups, and PFS between mCRC groups; a higher incidence of 1-year OS with FOLFOX in the mCRC setting was noted (p = 0.03). No difference was found in toxicity between FOLFOX and XELOX, except a higher incidence of hand-foot syndrome in XELOX (p = 0.0007). Conclusions: Efficacy between FOLFOX and XELOX in aCRC and mCRC is similar, while toxicity is slightly more prevalent in XELOX due to increased hand-foot syndrome incidence. These findings agreed with the results reported by prospective clinical trials.
TSTE, WOON YUEN KHEE KIM. "Cancer du sein : chimiotherapie adjuvante ; resultats a long terme d'une serie de patientes n+ traitees de 1978 a 1992 a la clinique sainte-catherine par cmf ou avcf adjuvant". Aix-Marseille 2, 1993. http://www.theses.fr/1993AIX20143.
Texto completoPARGA, NATHALIE. "La chimiotherapie adjuvante chez la femme non menopausee atteinte d'un cancer du sein avec envahissement ganglionnaire axillaire : etude de 107 cas traites et suivis a nantes". Nantes, 1994. http://www.theses.fr/1994NANT009M.
Texto completoQuack, Henriette [Verfasser], Torsten [Akademischer Betreuer] Liersch y Hendrik [Akademischer Betreuer] Wolff. "5-Fluorouracil-Spiegelbestimmung unter neoadjuvanter Radiochemotherapie und adjuvanter Chemotherapie beim lokal fortgeschrittenen Rektumkarzinom / Henriette Quack. Gutachter: Torsten Liersch ; Hendrik Wolff. Betreuer: Torsten Liersch". Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2015. http://d-nb.info/1070686131/34.
Texto completoCHINCHILLA, ERIC VICTOR. "Chimiotherapie neo-adjuvante associant cisplatine carboplatine et 5-fluorouracile dans les carcinomes epidermoides de la tete et du cou : a propos de 31 cas". Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1M027.
Texto completoJunior, Samuel Aguiar. ""Valor prognóstico e preditivo da expressão imunoistoquímica de timidilato sintase em pacientes portadores de adenocarcinoma colorretal"". Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-26102005-151553/.
Texto completoThe purpose of this study was trying to assess the value of TS expression as a predictive factor in the efficacy of adjuvant chemotherapy in colorectal cancer, as well as its independent prognostic value for survival. It deals with a retrospective study that assesses a series of 114 individuals with high risk colorectal cancer, distributed into two different groups: 1)surgery alone (n=61); 2)surgery and 5-FU-based chemotherapy (n=53). TS expression was determined by immunohistochemistry. We observed that TS expression may select patients that benefit from adjuvant chemotherapy, but it was not shown as an independent variable for the risk of recurrence or death
Quack, Henriette. "5-Fluorouracil-Spiegelbestimmung unter neoadjuvanter Radiochemotherapie und adjuvanter Chemotherapie beim lokal fortgeschrittenen Rektumkarzinom". Doctoral thesis, 2015. http://hdl.handle.net/11858/00-1735-0000-0022-5FD0-2.
Texto completoLibros sobre el tema "Adjuvant 5-Fluorouracil"
McLeon, Kelly. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. Editado por SreyRam Kuy y Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0011.
Texto completoCapítulos de libros sobre el tema "Adjuvant 5-Fluorouracil"
Vokes, E. E., W. R. Panje y R. R. Weichselbaum. "5-Fluorouracil modulation in head and neck cancer". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 54–57. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_13.
Texto completoCellerino, R., A. Piga, L. Latini, V. Saba, E. Cesini, G. L. Cetto, R. Bascioni, G. Corradini, A. Fianchini y E. Landi. "Preoperative 5-Fluorouracil in resectable colorectal cancer. Preliminary results of a prospective randomized trial". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 223–26. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_55.
Texto completoBalana, C., J. Minguell, B. Massuti, A. Arrivi y B. Sanchez. "Treatment of locally advanced head and neck cancer with Neo-Adjuvant Cisplatin (CDDP) and 5-Fluorouracil (5-FU) chemotherapy (CT)". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 76–79. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_19.
Texto completode Cremoux, H., N. Azli, S. Voisin, I. Monnet, P. Ruffié, M. Riggi, L. Vergnes, J. Huet, J. C. Saltiel y E. Cvitkovic. "Cisplatin, 5-Fluorouracil + Leucovorin and Vindesine, in non-small cell lung cancer : a phase II study". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 447–48. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_109.
Texto completoFety, R., J. Vignoud, P. Cappelaere, A. Pineau y P. Viau. "Pharmacokinetic study of Neo-Adjuvant chemotherapy combining Carboplatin, Cisplatin and 5-Fluorouracil in head and neck squamous cell carcinoma". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 389–91. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_94.
Texto completoVokes, Everett E., D. J. Haraf, W. R. Panje, J. M. McEvilly, M. F. Kozloff, D. Goldman, N. Clendeninn, A. G. Tybor, M. Collier y R. R. Weichselbaum. "Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 58–60. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_14.
Texto completoClark, J., A. Dreyfuss, C. Norris, P. Busse, C. Beard, J. Lucarini, J. Andersen, D. Miller, D. Casey y E. Frei. "Neo-Adjuvant Cisplatin, 5-Fluorouracil and high-dose Leucovorin for advanced head and neck cancer : response, toxicity, survival and comparison with historical controls". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 50–53. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_12.
Texto completoVincent, M., F. Levi, B. Girodet, E. Laennec, P. Poirie, B. Guibert, J. M. Ardiet, A. Boisson y L. Van-Straaten. "Circadian chemotherapy against stage IIIB-IV non-small-cell lung cancer (NSCLC) with 5-Fluorouracil (5-FU), folinic acid (FOL) and cisplatin (CDDP) via a multichannel programmable pump. Preliminary results". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 395–99. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_96.
Texto completoThiberville, L., C. Faure, J. Bouillard, J. Clavier, Ph David, J. P. Duhamel, J. Heintz et al. "Faster response and survival advantage with Neo-Adjuvant Cisplatin and 5-Fluorouracil infusion versus Cisplatin and Bleomycin in advanced non-small cell lung cancer". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 449–53. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_110.
Texto completoUrba, Susan, A. Forastiere, G. Wolf y A. Thornton. "Neo-Adjuvant chemotherapy for organ preservation with high dose continuous infusion of Cisplatin, 5-Fluorouracil, and Mitoguazone for head and neck cancer : a preliminary report". En Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 23–24. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_4.
Texto completoActas de conferencias sobre el tema "Adjuvant 5-Fluorouracil"
Kim, Yong-Jae, Jinseon Jeong, Ki-Young Sohn, Do Young Lee, Sun Young Yoon y Jae Wha Kim. "Abstract 360: Therapeutic potential of EC-18 as a chemotherapy adjuvant for 5-fluorouracil-induced neutropenia". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-360.
Texto completoKim, Yong-Jae, Jinseon Jeong, Ki-Young Sohn, Do Young Lee, Sun Young Yoon y Jae Wha Kim. "Abstract 360: Therapeutic potential of EC-18 as a chemotherapy adjuvant for 5-fluorouracil-induced neutropenia". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-360.
Texto completoOwusu-Brackett, N., S. Scott, E. Yuca, KW Evans, C. Tapia y F. Meric-Bernstam. "Abstract P1-13-04: Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy". En Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-13-04.
Texto completoLevine, M., A. Arnold, L. Kelleher, S. Lord, W. Hryniuk, J. Hrish y M. Gent. "CANCER CHEMOTHERAPY AND THROMBOSIS". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643203.
Texto completoMusa, Nafisah y Tin Wui Wong. "Nanoparticles-in-soft microagglomerates as oral colon-specific cancer therapeutic vehicle". En 3rd International Congress of Engineering Sciences and Technology. Facultad de Ciencias de la Ingeniería y Tecnología, 2021. http://dx.doi.org/10.37636/recit.cicitec21.1.
Texto completoNakamura, Jun, Yoshihiko Kitajima, Keita Kai, Kazuyoshi Hashiguchi, Masatsugu Hiraki, Hirokazu Noshiro y Kohji Miyazaki. "Abstract LB-376: Hypoxia-inducible factor-1 alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-fluorouracil chemotherapy". En Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-376.
Texto completoDelbaldo, C., D. Serin, M. Mousseau, S. Greget, B. Audhuy, F. Priou, J.-F. Berdah, E. Teissier, E. Quinaux y P. Piedbois. "Abstract P5-10-05: A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)". En Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-10-05.
Texto completoYonemori, K., S. Ohsumi, S. Takao, Y. Tokuda, Y. Ito, K. Nakagami, M. Takahashi et al. "Abstract P1-13-09: Long-term follow-up of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial) comparing oral tegafur-uracil (UFT) versus classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant therapy in early breast cancer". En Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-13-09.
Texto completoBrandberg, Yvonne, Nils-Olof Bengtsson, Richard Greil, Volker Möbus, Per Malmström, Hemming Johansson, Harald Andersson et al. "Abstract P1-13-12: [bold]The adjuvant PANTHER study - A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel – First report on q". En Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p1-13-12.
Texto completoMasuda, N., N. Sato, K. Higaki, M. Kashiwaba, N. Matsunami, T. Takano, J. Yamamura et al. "Abstract P1-14-08: A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study". En Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p1-14-08.
Texto completo